| CTRI Number |
CTRI/2026/01/100302 [Registered on: 05/01/2026] Trial Registered Prospectively |
| Last Modified On: |
30/04/2026 |
| Post Graduate Thesis |
No |
| Type of Trial |
PMS |
|
Type of Study
|
Medical Device |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
To evaluate the safety of Mirus Hemorrhoidal Circular Stapler among patients with hemorrhoids |
|
Scientific Title of Study
|
A prospective, single-arm, multicenter, real-world, post-market clinical follow-up study to evaluate the safety and performance of Mirus Hemorrhoidal Circular Stapler |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| MES/MIRUS HEMORRHOIDAL CIRCULAR STAPLER - 1 V1.0.0_01-Aug-25 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Kirankumar Shetty |
| Designation |
AGM - Product Performance & Engineering Department |
| Affiliation |
Meril Life Sciences Pvt. Ltd |
| Address |
Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad
Valsad GUJARAT 396191 India |
| Phone |
9743700109 |
| Fax |
|
| Email |
kirankumar.shetty@merillife.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Kirankumar Shetty |
| Designation |
AGM - Product Performance & Engineering Department |
| Affiliation |
Meril Life Sciences Pvt. Ltd |
| Address |
Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad
Valsad GUJARAT 396191 India |
| Phone |
9743700109 |
| Fax |
|
| Email |
kirankumar.shetty@merillife.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Kirankumar Shetty |
| Designation |
AGM - Product Performance & Engineering Department |
| Affiliation |
Meril Life Sciences Pvt. Ltd |
| Address |
Buiding number 6, 3rd floor, Near Bilakhia Stadium, Survey no 135,139,Muktanand marg, Chala, Vapi-396191, Gujarat, India Valsad
Valsad GUJARAT 396191 India |
| Phone |
9743700109 |
| Fax |
|
| Email |
kirankumar.shetty@merillife.com |
|
|
Source of Monetary or Material Support
|
| Meril Endosurgery Pvt.Ltd.MERIL PARK , E1-E3, SURVEY NO 135/2/B, 174/2, MUKTANAND MARG, CHALA, VAPI,VALSAD,GUJARAT,396191 |
|
|
Primary Sponsor
|
| Name |
Meril Life Sciences Pvt Ltd |
| Address |
Near Bilakhia Stadium, Survey no 135/139,Muktanand marg, Chala, Vapi-396191, Gujarat, India |
| Type of Sponsor |
Other [Medical Device Company] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
Sites of Study
Modification(s)
|
| No of Sites = 4 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Shashank Trivedi |
GBH American Hospital |
Department of General Surgery, Ground floor Meera Girls, 20-BHATT JI KI BARI, 101, Kothi Bagh, College Road, Kothi Bagh, Udaipur, Rajasthan 313004 Udaipur RAJASTHAN |
9638338726
shashankjtrivedi@gmail.com |
| Dr Sahdevsinh Chauhan |
Hanumant Hospital |
5th & 6th Floor, Anjaneya Icon, Kalubha Rd, opposite Surydeep Complex, Nanbhawadi, Panwadi, Bhavnagar, Gujarat 364001 Bhavnagar GUJARAT |
9737506070
hanumanthospitals@gmail.com |
| Dr Nilesh Dhariya |
Initimate Clinic |
Laproscopic Department,E-86, LIG Link Rd, near Lifeline Hospital, Shree Nagar Ext, Pushpa Nagar, Anurag Nagar, Indore, Madhya Pradesh 452011 Indore MADHYA PRADESH |
7509355565
info@intimateclinic.in |
| Dr Rakesh Shivhare |
Pristyn Care Eminent Superspeciality Hospital |
Pristyn Care, Eminent Hospital, Manorama Ganj, opp. Barwani Plaza Residential Road, Near Eureka Hospital, Old Palasia, Indore, Madhya Pradesh 452018 Indore MADHYA PRADESH |
9826680273
drrakeshshivhare@gmail.com |
|
Details of Ethics Committee
Modification(s)
|
| No of Ethics Committees= 4 |
| Name of Committee |
Approval Status |
| GBH Memorial Cancer Hospital Ethics Committee |
Approved |
| kiran Institutional Ethics Committee |
Approved |
| Rectitude Ethics Committee |
Submittted/Under Review |
| Rectitude Ethics Committee |
Submittted/Under Review |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: K649||Unspecified hemorrhoids, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
NIl |
NIL |
| Comparator Agent |
NIL |
NIL |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
99.00 Year(s) |
| Gender |
Both |
| Details |
1.Participants aged 18 years or older, regardless of gender who undergo surgical treatment of hemorrhoidal disease throughout the anal canal using the Mirus™ Hemorrhoidal Circular Stapler.
2.Participants who are able to give voluntary, written informed consent to participate in this PMCF and from whom consent has been obtained. |
|
| ExclusionCriteria |
| Details |
1.Participants who are unwilling or unable to sign the Informed Consent Document.
2.Participants with compressed tissue thickness less than 0.75 mm or greater than 1.5 mm.
3.Participants whose rectum internal diameter will not accommodate the instrument and accessories.
4.Participants with anal stenosis, severe mucosal edema, and severe fibrosis of hemorrhoidal tissue
5.Participants with necrotic or friable tissues and tissues having altered integrity.
6.Participants whose hemorrhoidal tissue has undergone multiple injections of hardening agents.
7.Participants currently undergoing anticoagulation therapy.
8.Participants with any anatomical or pathological condition that would compromise safe stapler placement or function.
9.Participants unable to achieve adequate tissue compression within the specified thickness parameters. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
1.Recurrence Rate
2. Stapled Hemorrhoidopexy Complications |
1. Time Frame: 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days.
2.Time Frame: Intra-operative, Discharge, 3 months ± 7 days, 6 months ± 7 days, 1 year ± 30 days |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
1.Quality of Life
2.Pain
3.Operative Time
4. Length of Hospital Stay
5. Adverse events |
1. Time Frame: Baseline, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days.
2.Time Frame: Baseline, Discharge, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days
3.Time Frame: Intra-operative
4.Time Frame: Discharge
5.Time Frame: Discharge, 3 months ± 7 days, 6 months ± 7 days, and 1 year ± 30 days |
|
|
Target Sample Size
|
Total Sample Size="134" Sample Size from India="134"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Post Marketing Surveillance |
|
Date of First Enrollment (India)
|
19/01/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Study Name:A prospective, single-arm, multicenter, real-world, post- market clinical follow-up study to evaluate the safety and performance of Mirus Hemorrhoidal Circular Stapler. Short Title:Mirus Hemorrhoidal Circular Stapler Protocol ID, Version & Date:MES/MIRUS HEMORRHOIDAL CIRCULAR STAPLER - 1_Version 1.0.0_01-Aug-2025 Study Device:Mirus™ Hemorrhoidal Circular Stapler Indication:Mirus™ Hemorrhoidal Circular Stapler has application throughout the anal canal to perform surgical treatment of hemorrhoidal disease. Contraindication: Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids where the compressed tissue thickness is less than 0.75 mm or greater than 1.5 mm or where the rectum internal diameter will not accommodate the instrument and accessories. If the instrument is used on tissue less than 0.75 mm or greater than 1.5 mm thick, it may result in staple malformation or hemorrhage. 2. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when anal stenosis exists. 3.Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when severe mucosal edema exists. 4. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when severe fibrosis of hemorrhoid tissue exists. 5. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids when tissue has undergone multiple injections of a hardening agent at hemorrhoids. 6. Do not use Mirus™ Hemorrhoidal Circular Stapler for Prolapse and Hemorrhoids on the participants undergoing anti coagulation therapy. 7.Mirus™ Hemorrhoidal Circular Stapler should not be used to staple necrotic, friable tissues or have altered integrity, e.g., ischemic or edematous tissues. Objective:The study aims to evaluate the safety and performance of Mirus™ Hemorrhoidal Circular Stapler.
Hemorrhoidal disease is one of the most common conditions identified in outpatient clinics, resulting in 3.3 million outpatient visits annually in the U.S., with a self-reported incidence of 10 million cases per year, affecting 4.4% of the population Currently, treatment options for hemorrhoidal disease (HD) range from conservative approaches, such as dietary changes and medications, to non-excisional methods like cryotherapy, sclerotherapy, laser photocoagulation, and rubber band ligation. For advanced cases, particularly grade III or IV hemorrhoids, or when conservative treatments fail in patients with persistent bleeding, surgical excision may be necessary . Surgery is the most effective treatment for hemorrhoids and is particularly recommended for grade IV hemorrhoids (irreducible) and prolapsing hemorrhoids during defecation that may be manually reduced . Traditional hemorrhoidal surgery, including Ferguson’s and Milligan-Morgan procedures, effectively removes hemorrhoids but causes significant postoperative pain due to external wounds. Stapled hemorrhoidopexy, introduced by Longo, has gained widespread acceptance for causing less pain and enabling faster recovery. This technique utilizes a specially designed circular stapling device that differs from traditional circular staplers used for creating full-thickness anastomoses . Pain is the most common complication following hemorrhoidectomy procedures. Long-term complications include anal fissure, anal stenosis, incontinence, fistula, and hemorrhoidal recurrence. The significant pain associated with hemorrhoidectomies represents a major clinical concern . The recently introduced laser hemorrhoidoplasty technique has been successfully applied to patients with hemorrhoids of all degrees. This method delivers laser energy into the interstitial tissue rather than the perianal vessels, resulting in tissue retraction and hemorrhoidal resolution. The technique produces less intense, shorter-duration pain and achieves satisfactory long-term outcomes. The distinctive feature of laser hemorrhoidoplasty is that the coagulated area remains invisible during the procedure since it lies beneath the healthy, uninjured mucosal layer. |